Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tuxobertinib - Black Diamond Therapeutics

Next Previous
Drug Profile

Tuxobertinib - Black Diamond Therapeutics

Alternative Names: BDTX-189

Latest Information Update: 12 Oct 2022

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Black Diamond Therapeutics
  • Class Acrylamides; Antineoplastics; Morpholines; Pyridines; Quinazolines; Small molecules
  • Mechanism of Action Epidermal growth factor receptor antagonists; ERBB 2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Solid tumours

Most Recent Events

  • 03 Oct 2022 Black Diamond Therapeutics terminates the phase I/II MasterKey-01 trial in Solid tumours (Late-stage disease, Second-line therapy or greater) in USA, Denmark, France, Italy, Netherlands, Spain, Poland (PO) as the development was discontinued by the sponsor (NCT04209465) (EudraCT2020-005492-12)
  • 25 Apr 2022 Discontinued - Phase-I/II for Solid tumours (Late-stage disease, Second-line therapy or greater) in Denmark, France, Italy, Netherlands, Poland, Spain (PO) (NCT04209465) (EudraCT2020-005492-12)
  • 25 Apr 2022 Discontinued - Phase-I/II for Solid tumours (Late-stage disease, Second-line therapy or greater) in USA (PO)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top